Mutations in STK11 gene in Czech Peutz-Jeghers patients

Peter Vasovcák1, Alena Puchmajerová, Jan Roubalík

  • 1Department of Biology and Medical Genetics, Charles University 2nd Medical School, University Hospital Motol, Prague, Czech Republic. pevas78@hotmail.com

BMC Medical Genetics
|July 21, 2009
PubMed

Insights

Genetic testing for Peutz-Jeghers syndrome (PJS) identified STK11 gene mutations in families meeting PJS criteria and in some sporadic cases. A patient with an STK11 frameshift mutation developed aggressive gastric cancer.

Area of Science:

  • Genetics and Genomics
  • Oncology
  • Hereditary Cancer Syndromes

Background:

  • Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder linked to STK11 gene mutations.
  • PJS patients face an elevated risk of developing various neoplasms.
  • Characterizing genotype-phenotype correlations in PJS is crucial for risk assessment.

Observation:

  • This study investigated STK11 gene mutations in Czech PJS patients using sequencing and MLPA.
  • Genomic DNA from 8 individuals across five families and three sporadic cases was analyzed.
  • The analysis covered the STK11 gene's promoter, coding, and splice-site regions.

Findings:

  • Pathogenic STK11 mutations were identified in two PJS families and one of three sporadic cases.
  • A patient with an STK11 frameshift mutation developed aggressive gastric cancer.
  • No other participants have developed carcinoma to date.

Implications:

  • STK11 mutations are present not only in classic PJS but also in some sporadic cases.
  • This finding expands the spectrum of clinical presentations associated with STK11 mutations.
  • Early identification of STK11 mutations can aid in cancer surveillance and management.
Abstract

Related Concept Videos

Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Karyotyping01:17

Karyotyping

Describing the number and physical features of chromosomes can reveal abnormalities that underlie genetic diseases. This description is facilitated by special staining techniques that produce a particular banding pattern on each chromosome. State-of-the-art techniques make this approach even more powerful, enabling the detection of individual genes that cause disease.A Simple Chromosome Staining Technique Provides Valuable Scientific InsightSome genetic diseases can be detected by looking at...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Mutations01:39

Mutations

Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...